“We have been testing the Altoida technology since June 2018 in specific clinical settings and the technology looks extremely promising. It is exactly what we have been looking for to improve our day to day routine, since the prevention of cognitive impairment in persons at risk of Alzheimer’s Disease/MCI and therefore prolonging the onset of AD, is much more important than treating already advanced patients. Altoida cognitive assessment technology for everyday functions will assist clinicians in identifying these risks in a reliable and gamified way.” said Dr. med. Henry Perschak Hirslanden AGKlinik Zürich, Switzerland